PharmaDeals Review: Latest Articles
All the latest analysis of deal-making activity in the pharmaceutical and biotechnology sector provided by the experts from the PharmaDeals Review.
- Published on: 2008-06-18 GlaxoSmithKline Boosts its Infectious Disease Portfolio This month GSK has entered into a collaboration for developing novel antibiotic products and has also beaten Sanofi-Pasteur’s Gardasil® to gain the contract for supply of Cervarix® for the UK HPV immunisation programme.
- Published on: 2008-06-17 Boehringer Ingelheim’s Structured Venture into Biotech Boehringer Ingelheim’s acquisition of US biotech Actimis, for the one aim of gaining rights to a small molecule asthma treatment, implements an unusual deal structure heavily dependent on the achievement of certain milestones.
- Published on: 2008-06-12 Daiichi Sankyo Diversifies into Generics through Major Investment in Indian Giant Several overseas acquisitions by Japanese companies have taken place over the last few months, with Daiichi Sankyo being the latest company taking steps to do so. Its venture, however, is a lot closer to home.
- Published on: 2008-06-06 Ipsen Expands Existing US Base through Acquisitions Worth $458 Million French speciality pharma Ipsen, whose targeted therapeutic areas are oncology, endocrinology and neuromuscular disorders, is acquiring a fully fledged US presence by acquiring Octagen, Tercica and the US subsidiary of the UK's Vernalis.
- Published on: 2008-06-04 Novartis Gains MRSA Product Through Acquisition of Protez Pharmaceuticals Novartis gains a superbug-targeting antibiotic through this acquisition of Protez Pharmaceuticals.
- Published on: 2008-05-29 BMS Bags a Bargain BMS has agreed to buy Kosan Biosciences for US$190 M. For a company with a Phase III product in its pipeline, did Kosan get what it deserves?
- Published on: 2008-05-29 Sonus Finds Way Out through Merger with OncoGenex Sonus Pharmaceuticals has overcome disappointing Phase III failure in late 2007 by merging with OncoGenex to form OncoGenex Pharmaceuticals, a company with an array of promising oncology clinical candidates.
- Published on: 2008-05-27 Alnylam and Takeda Form RNAi Partnership Japanese company, Takeda Pharmaceutical, has strengthened it oncology pipeline through this RNAi alliance with US biotech, Alnylam Pharmaceuticals.
- Published on: 2008-05-22 Lundbeck Gains European Rights for Alzheimer’s Drug H. Lundbeck has received European commercialisation rights for Myriad Genetics’ Phase III Alzheimer’s therapeutic, Flurizan® (tarenflurbil), agreeing to impressive financial terms in the process.
- Published on: 2008-05-21 Daiichi Sankyo Boosts Oncology Portfolio with Acquisition of Biotech, U3 Pharma Daiichi Sankyo is to acquire German oncology biotech, U3 Pharma, for €150 M (US$234 M), boosting the Japanese company’s biologics pipeline.
Last Issue PDF
RSS